NEW YORK (GenomeWeb) – Avalon GloboCare said today that its newly formed, majority-owned subsidiary GenExosome Technologies has acquired 100 percent of the outstanding capital stock of a Chinese exosome technology company called Beijing Jieteng (Beijing GenExosome) Biotech.

The new Avalon-owned GenExosome subsidiary has also closed an asset purchase agreement with the Beijing firm's CEO Yu Zhou, which pertains to Zhou's IP, patents and patent applications for research, development, and commercialization of exosome technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.